Evidence map›Paper›PMID 40970816›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Modeling Midbrain and Brainstem Neuromelanins to Characterize Metal Binding and Associated MRI Contrast in Parkinson's and Alzheimer's Diseases.

Niklas Wallstein, Andrea Capucciati, Andreas Pöppl, Claudia S Schnohr, Michela Sturini, André Pampel, Carsten Jäger, Luigi Zecca, Fabio A Zucca, Enrico Monzani and 2 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Niklas WallsteinNMR Methods & Development Group, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstraße 1A, 04103, Leipzig, Germany.ORCID 0009-0003-4952-7962
Andrea CapucciatiDepartment of Chemistry, University of Pavia, Via Taramelli 12, Pavia, 27100, Italy.ORCID 0000-0002-2731-3547
Andreas PöpplFelix Bloch Institute for Solid State Physics, Leipzig University, Linnéstraße 5, 04103, Leipzig, Germany.ORCID 0000-0003-2354-2542
Claudia S SchnohrFelix Bloch Institute for Solid State Physics, Leipzig University, Linnéstraße 5, 04103, Leipzig, Germany.ORCID 0000-0002-3688-7104
Michela SturiniDepartment of Chemistry, University of Pavia, Via Taramelli 12, Pavia, 27100, Italy.ORCID 0000-0002-8122-6188
André PampelNMR Methods & Development Group, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstraße 1A, 04103, Leipzig, Germany.ORCID 0000-0002-9319-5016
Carsten JägerDepartment of Neurophysics, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstraße 1A, 04103, Leipzig, Germany.ORCID 0000-0001-6512-9903
Luigi ZeccaInstitute of Biomedical Technologies, National Research Council of Italy, Via Cervi 93, Segrate, Milan, 20054, Italy.ORCID 0000-0002-7409-6653
Fabio A ZuccaInstitute of Biomedical Technologies, National Research Council of Italy, Via Cervi 93, Segrate, Milan, 20054, Italy.ORCID 0000-0003-1230-1129
Enrico MonzaniDepartment of Chemistry, University of Pavia, Via Taramelli 12, Pavia, 27100, Italy.ORCID 0000-0002-8791-6446
Luigi CasellaDepartment of Chemistry, University of Pavia, Via Taramelli 12, Pavia, 27100, Italy.ORCID 0000-0002-7671-0506
Harald E MöllerNMR Methods & Development Group, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstraße 1A, 04103, Leipzig, Germany.ORCID 0000-0002-5659-1925

Funding

Italian Ministry of University and Research (MUR)-"InvAt Project-Active and Healthy Aging (FOE 2022)"Max Planck Society (HEM) and the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity (NW)Pezzoli Foundation for Parkinson's disease (Milan, Italy)University of Pavia, "Dipartimenti di Eccellenza 2023-2027"
6 · The paper itself

Abstract

Neuromelanin (NM) is a dark pigment that binds potentially toxic metal ions and is crucial for neuronal vulnerability. Magnetic resonance imaging (MRI) was proposed to measure neuromelanin in the substantia nigra or locus coeruleus, potentially providing a marker of Parkinson's disease. Here, synthetic neuromelanin analogues were prepared with iron and copper and used for characterization of metal binding and impact on proton relaxation, a prerequisite for optimizing neuromelanin-sensitive MRI. The results confirm the presence of paramagnetic mononuclear Fe(III) and antiferromagnetically coupled clusters, which enhance relaxation to variable degrees. Further complexity arises from Cu(II), which can compete for binding to mononuclear sites, aggregate in mixed-metal clusters, or bind to proteins associated with the melanin moiety. Unlike the strong relaxant Fe(III), Cu(II) only indirectly impacts relaxation by replacing iron. Overall, MRI primarily provides measures of average neuromelanin concentrations. Information on the distribution of neuromelanins with different metal compositions might be obtained with multiparametric MRI.

Indexed as

Alzheimer DiseaseBrain StemContrast MediaMagnetic Resonance ImagingMelaninsMesencephalonParkinson DiseaseCopperHumansIronContrast MediaCopperIronMelaninsneuromelaninBioinorganic chemistryCopperIronMagnetic resonanceNeuromelanin

Identifiers

PMID40970816
PMCPMC12501727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.